Relmada Therapeutics
RLMD
45 hedge funds and large institutions have $1.68M invested in Relmada Therapeutics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 12 closing their positions.
7.22% less ownership
Funds ownership: 27.85% → 20.63% (-7.2%)
8% less funds holding
Funds holding: 49 → 45 (-4)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
71% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 14
86% less capital inflows, than outflows
Capital inflows: $139K | Capital outflows: $1.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$40.1K |
| 2 |
Two Sigma Advisers
New York
|
+$29.5K |
| 3 |
AdvisorShares Investments
Bethesda,
Maryland
|
+$22K |
| 4 |
HRT Financial
New York
|
+$17.3K |
| 5 |
Two Sigma Investments
New York
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$417K |
| 2 |
Tang Capital Management
San Diego,
California
|
-$104K |
| 3 |
Barclays
London,
United Kingdom
|
-$75.9K |
| 4 |
GSA Capital Partners
London,
United Kingdom
|
-$65K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$64K |
RLMD Hedge Fund Activity: Q1 2025 in Review
45 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2025, worth a combined $1.68M — down 62% from $4.36M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RLMD and 7 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 4 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $40.1K. The largest seller was Franklin Resources, cutting an estimated $417K.
- 45 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2025, down from 49 in Q4 2024.
- Funds reported $1.68M of Relmada Therapeutics stock for Q1 2025, down 62% quarter-over-quarter.
- 7 funds opened new Relmada Therapeutics positions in Q1 2025 and 12 closed out, a net change of -5 holders.
- The largest Relmada Therapeutics buyer in Q1 2025 was Goldman Sachs, an estimated $40.1K added.
- The largest Relmada Therapeutics seller in Q1 2025 was Franklin Resources, an estimated $417K sold.
Based on aggregated 13F filings for Q1 2025.